https://www.sec.gov/Archives/edgar/data/1403570/00

New Post Public Reply Private Reply Replies (0) Message Board
solartech Quisbo #14450
493
https://www.sec.gov/Archives/edgar/data/14035...-index.htm

ARTICLE IV

FINANCIAL TERMS

Section 4.1 Upfront Fee . The Licensee shall pay the Licensor an upfront payment of $500,000.00 within [30] business days after the Effective Date and an additional $500,000.00 within 60 days after the effective date .

Section 4.2 Purchase of Equipment .

(a) Reactors . The Licensee shall purchase two (2) production reactors used for the production of Licensed Products for an aggregate purchase price of $ [**Confidential Treatment Requested] , payable as follows:

(i) $ [**Confidential Treatment Requested] shall be payable within 60 business days after the Effective Date;
(ii) $ [**Confidential Treatment Requested] shall be payable immediately upon delivery to the licensees designated freight forwarder; and
(iii) $ [**Confidential Treatment Requested] shall be payable when the reactors are received, setup and operational, as determined by the Licensor.

[**Confidential Treatment Requested] indicates that portions of this document have been redacted and filed separately with the Securities and Exchange Commission.

(b) Schlenk Line Equipment . The Licensee shall purchase the automated equipment for two (2) Schlenk lines from the Licensor for an aggregate purchase price of $ [**Confidential Treatment Requested] , payable 50% with order and 40% upon delivery to licensees designated freight forwarder and balance once equipment is received, setup and operational as determined by Licensor.

(c) Inline Equipment . The Licensee shall purchase the inline laminating, printing and associated equipment from the Licensor for an aggregate purchase price of $ [**Confidential Treatment Requested] , payable 50% with order and 40% upon delivery to licensees designated freight forwarder and balance once equipment is received, setup and operational as determined by Licensor.

(d) Other Equipment . The Licensee shall purchase related to the License and Licensed Products exclusively from the Licensor at the Licensor’s then-prevailing prices and terms.

Section 4.3 Consulting and Training .

(a) Training . For a period of 36 following the Effective Date, the Licensor shall provide training to the Licensee’s employees and contractors in connection with the manufacturing of the Licensed Products, as the mutually agreed by the Parties, as mutually agreed between the Parties. The fees for such consulting services will be billed at the Licensor’s then-prevailing hourly rates for such services. As of the date of this Agreement, it is anticipated that the average rate for such services will be approximately $ [**Confidential Treatment Requested] per hour, which may vary depending on the nature of the training, the experience and specialized expertise of the personnel performing such training and other economic factors at such time. Amounts payable in respect of services under this Section 4.3(a) shall be invoiced to the Licensee monthly in arrears and paid to the Licensor, as directed by the Licensor, which amounts shall be due within thirty (30) days after the date of invoice.

(b) Consulting .

(i) Facility Design . The Licensee shall pay an aggregate amount of approximately $ [**Confidential Treatment Requested] in connection with the Licensor’s consulting services related to the design of the Manufacturing facility, payable under terms and conditions to be negotiated.

(ii) Other Consulting . For a period of 5 years following the Effective Date, the Licensor agrees to provide consulting services for the implementation and operation of the items set forth in Section 4.2 and the Manufacturing of Licensed Products, as mutually agreed between the Parties. The fees for such consulting services will be billed at the Licensor’s then-prevailing hourly rates for such services. As of the date of this Agreement, it is anticipated that the average rate for such services will be approximately $ [**Confidential Treatment Requested] per hour, which may vary depending on the nature of the services, the experience and specialized expertise of the consultant performing such services and other economic factors at such time. Amounts payable in respect of services under this Section 4.3(b) shall be invoiced to the Licensee monthly in arrears and paid to the Licensor, as directed by the Licensor, which amounts shall be due within thirty (30) days after the date of invoice.

[**Confidential Treatment Requested] indicates that portions of this document have been redacted and filed separately with the Securities and Exchange Commission.

Section 4.4 Royalty .

(a) Royalty Amounts . Subject to the terms and conditions of this Agreement, in consideration of the rights and licenses granted herein, the Licensee shall pay to the Licensor a royalty equal to [**Confidential Treatment Requested] percent ( [**Confidential Treatment Requested] %) of Gross Sales (collectively, the “ Royalty ”).

(b) Payment Timing . The Royalty shall be paid quarterly (the “ Royalty Period ”), within ten (10) days after the end of the relevant calendar quarter for which royalties are due.

(c) Royalty Payment Reports . With respect to each Royalty Period, at the time(s) when the payments of Section 4.4(b) are due, the Licensee shall provide to the Licensor a written report stating the number and description of all items sold during the Royalty Period, the Gross Sales associated with such sales, and the calculation of Gross Sales on such sales. The report shall provide all such information on a country-by-country and product-by-product basis.

(d) Records . The Licensee shall keep, for a period of six (6) years following the end of the calendar year to which such records relate, and ensure that its Affiliates keep, complete and accurate records of its sales to which Royalties may apply, including all records that may be necessary for the purposes of calculating all payments due under this Agreement. The Licensee shall make such records available for inspection to the Licensor, including the Licensor’s accounting, financial and legal representatives, at the Licensee’s premises on reasonable notice during regular business hours.

(e) Audit. No more than once per calendar year, the Licensor shall have the right to retain an independent certified public accountant to perform on behalf of the Licensor an audit of such books and records of the Licensee and its Affiliates as are necessary (in the reasonable opinion of the auditor) to verify Gross Sales for the period or periods requested by the Licensor and the accuracy of any report or payments made under this Agreement. If an audit reveals an underpayment, the Licensee shall promptly pay to the Licensor the amount of such undisputed underpayment [plus interest] in accordance with Section 4.4(a) . If the audit reveals that the undisputed monies owed by the Licensee to the Licensor has been understated by more than fifteen percent (15%) for any calendar year, the Licensee shall, in addition, pay the reasonable costs of such audit.]

(f) Licensee/Sublicensee Reports, Records and Audits . If the Licensee grants any licenses or sublicenses with respect to the Licensed Products or Licensed Technology, the agreements, certificates, documents and other instruments for such licenses and sublicenses shall include an obligation for the sublicensee to (i) provide reports with sufficient information to allow such verification in accordance with Section 4.4(c) ; (ii) maintain, for a period of six (6) years following the end of the calendar year to which such records relate, records adequate to document and verify the proper payments to be paid to the Licensor hereunder in accordance with Section 4.4(d) ; and (iii) allow the Licensor (or the Licensee if requested by the Licensor) to verify the payments due in accordance with Section 4.4(e) .

Section 4.5 Expenses . The Licensor shall pay or reimburse all reasonable travel and other related costs, expenses and fees incurred by the Licensor arising from, in connection with, or related to the commissioning and supervision activities relating to this Agreement, the MOU and the other agreements, certificates, documents and other instruments related thereto.

Annual minimum royalties will commence on January 15, 2021 and will be as follows:

January 15th , 2021 Minimum royalty = $[**Confidential Treatment Requested]
January 15th , 2022 Minimum royalty = $[**Confidential Treatment Requested]
January 15th , 2023 Minimum royalty = $[**Confidential Treatment Requested]
January 15th , 2024 Minimum royalty = $[**Confidential Treatment Requested]
January 15th , 2025 Minimum royalty = $[**Confidential Treatment Requested]

Since robust sales are anticipated from 2025 forward annual minimum royalties will likely no longer be relevant. In the event this is not the case annual minimum royalties of $[**Confidential Treatment Requested] will be used as default to perpetuity.

[**Confidential Treatment Requested] indicates that portions of this document have been redacted and filed separately with the Securities and Exchange Commission.























Quantum Materials Corp. (QTMM) Stock Research Links

QTMM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 3

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 3

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading

Top 5 Most Recently Viewed Articles

Isopropanol Market Expected to Reach US$ 6.95 Billion

Updated Category News Views 107

Overview of the Global Isopropanol Market A recent report indicates that the global isopropanol market is set to grow from USD 3.43 billion to USD 6.95 billion, achieving a compound annual growth rate (CAGR) of 7.3% during the forecast period. The Asia Pacific region is expected to dominate the market, capturing a significant share of the revenue. This growth is largely...

Continue Reading
Dynatrace Launches Innovative Observability Solutions for Devs

Updated Category News Views 517

Observability Solutions Tailored for Developers LAS VEGAS-- Dynatrace (NYSE: DT), a leader in AI-powered observability, recently announced the launch of Observability for Developers. This comprehensive suite of solutions aims to equip the developer community with essential runtime insights and troubleshooting capabilities, accelerating the much-needed 'shift-left'...

Continue Reading
Man Group PLC Shares and Position Disclosure Insights

Updated Category News Views 111

Understanding Man Group PLC's Position Disclosure Man Group PLC, a prominent global investment management firm, recently shared a crucial disclosure regarding its interests in securities related to Tritax Big Box REIT plc. This disclosure, in alignment with the UK Takeover Code, is pivotal for transparency and investor awareness. Notably, the firm has reported holding...

Continue Reading
Blackbaud Finalizes Sale of EVERFI to Private Investment Firm

Updated Category News Views 863

Blackbaud Completes Sale of EVERFI Blackbaud, Inc. (NASDAQ: BLKB), a leading software company that prioritizes social impact, has finalized the sale of its EVERFI business. This decision aligns with Blackbaud's ongoing focus on its core services and strategic objectives. Financial Overview and Strategic Review The sale, which was made to a private investment firm, is set...

Continue Reading
Apple's Strategic Move into AI-Enabled Smartphones Revealed

Updated Category News Views 175

Apple's Market Position and Recent Developments Apple (NASDAQ: AAPL) continues to hold its title as the world’s most valuable company, with an impressive market capitalization of about $3.3 trillion. The surge in demand for Apple's flagship device, the iPhone, plays a crucial role in reaching this valuation. However, recent reports indicate a dip in stock prices...

Continue Reading